Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure and is selective for phosphodiesterase 3. [1]

2007年10月20日 · Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is …

Enoximone is an imidazolone derivative currently undergoing trials in patients with congestive heart failure refractory to conventional therapy. It is a phosphodiesterase inhibitor with both …

Enoximone is a phosphodiesterase type-3 inhibitor that exerts most effect on the myocardium; it has positive inotropic properties and vasodilator activity. Indications and dose For enoximone

2012年10月31日 · Enoximone is an imidazolone derivative currently undergoing trials in patients with congestive heart failure refractory to conventional therapy. It is a phosphodiesterase …

Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients …

The primary objective is a reduction in auto-positive end-expiratory pressure (PEEP) after enoximone compared to baseline. A dose-titration will test for dose dependency. Secondary …

Enoximone is an imidazole derivative with selective PDE III inhibition. It is useful for the short-term support of cardiac output in patients with chronic heart failure, in whom elevated …

本品在肝、脾、肾及白血病细胞中逐渐代谢转化成阿糖胞苷，后者抑制DNA合成而显示抗肿瘤作用。 英文名称：Enoximone (MDL-17043,Fenoximone) 、 氢甲苯咪酮，甲硫咪唑酮，腈甲咪酮. …

2007年2月1日 · 本药为选择性强效的磷酸二酯酶Ⅲ型抑制剂，有明显增加心肌收缩力和扩张血管作用，能增加心排出量、心脏指数、左室心搏做功指数、降低右房压、肺毛细血管契嵌压、平均 …